Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California
07 juin 2023 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of...
Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis
30 mai 2023 09h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s Program
22 mai 2023 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
19 mai 2023 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors
18 mai 2023 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies...
Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy
10 mai 2023 16h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary
10 mai 2023 10h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy Manufacturing
25 avr. 2023 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022
21 mars 2023 08h00 HE
|
Orgenesis Inc.
Rapid growth reflects progress of POCare Platform Orgenesis to host conference call today at 11:00 AM ET GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS)...
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
17 mars 2023 09h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...